Form 4: Astrana Health COO/CFO Sells Shares for Tax Obligations

Chandan Basho, Astrana Health's COO and CFO, disposed of 1,979 common shares on October 2, 2025, to satisfy tax withholding obligations from vested restricted stock units.

Summary

• Chandan Basho, COO and CFO of Astrana Health, Inc. (ASTH), reported a transaction on October 2, 2025.
• Basho disposed of 1,979 shares of common stock at a price of $27.77 per share.
• This disposition was to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Basho beneficially owns 174,967 shares directly.
• The remaining beneficial ownership includes 7,214 unvested restricted shares vesting on April 14, 2026.
• An additional 30,404 unvested restricted shares will vest in two equal annual installments on May 16, 2026, and May 16, 2027.
• 19,504 restricted stock units will vest in five equal semi-annual installments starting April 2, 2026.
• 23,364 restricted stock units will vest in seven equal semi-annual installments starting March 5, 2026.
• All future vesting is subject to continuous employment with Astrana Health, Inc.

Sentiment

Score: 6

Explanation: The transaction is a routine, non-discretionary sale for tax purposes, which is generally neutral. The continued significant unvested equity holdings of the COO and CFO are a positive for long-term alignment.

Positives

• The transaction is a non-discretionary sale to cover tax obligations, indicating a routine event rather than a lack of confidence.
• The vesting of restricted stock units implies the achievement of prior performance or tenure conditions.
• Significant unvested equity remains, aligning management's interests with long-term shareholder value.

Negatives

• A reduction in direct insider ownership, albeit for a routine tax purpose.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the scheduled vesting of equity awards.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common across all industries for executives receiving equity compensation. It does not provide specific insights into broader industry trends or competitive landscape for Astrana Health.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a routine tax-related sale, not indicative of a change in management's confidence. The remaining significant equity holdings suggest continued alignment.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Vesting of 7,214 restricted shares on April 14, 2026.
• First of two equal annual installments for 30,404 restricted shares on May 16, 2026.
• First of five equal semi-annual installments for 19,504 restricted stock units starting April 2, 2026.
• First of seven equal semi-annual installments for 23,364 restricted stock units starting March 5, 2026.
• Second of two equal annual installments for 30,404 restricted shares on May 16, 2027.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by a key executive to cover tax obligations upon the vesting of restricted stock units. Such transactions are common and do not typically signal a change in the company's fundamentals or the executive's long-term commitment. The executive retains a substantial beneficial ownership, including significant unvested equity, which aligns their interests with shareholders. Therefore, this filing alone does not warrant a change in investment recommendation; a 'hold' stance is appropriate as it provides no new material information to alter the investment thesis.

Keywords

Astrana Health, ASTH, Chandan Basho, COO, CFO, Insider Trading, Form 4, Restricted Stock Units, Tax Withholding, Equity Compensation, Beneficial Ownership